IMPROVEDD VTE risk score: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
No edit summary |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 4: | Line 4: | ||
{{SK}} | {{SK}} | ||
==Overview== | ==Overview== | ||
The IMPROVEDD VTE Risk Score, which incorporates [[D-dimer]] measurement into the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) score, refines the prediction of symptomatic [[venous thromboembolism]] (including symptomatic [[deep-vein thrombosis]], nonfatal [[pulmonary embolism]], and death related to [[venous thromboembolism]]) events in acutely ill hospitalized patients up to 77 days of hospitalization. | The IMPROVEDD VTE Risk Score, which incorporates [[D-dimer]] measurement into the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) score, refines the prediction of symptomatic [[venous thromboembolism]] (including symptomatic [[deep-vein thrombosis]], nonfatal [[pulmonary embolism]], and death related to [[venous thromboembolism]]) events in acutely ill hospitalized patients up to 77 days of hospitalization. | ||
==IMPROVEDD VTE Risk Score== | ==IMPROVEDD VTE Risk Score== | ||
The IMPROVEDD VTE Risk Score, which incorporates [[D-dimer]] measurement into the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) score, refines the prediction of symptomatic [[venous thromboembolism]] (including symptomatic [[deep-vein thrombosis]], nonfatal [[pulmonary embolism]], and death related to [[venous thromboembolism]]) events in acutely ill hospitalized patients up to 77 days of hospitalization.<ref>{{cite journal | author=Gibson CM, Spyropoulos AC, Cohen AT, Hull RD, Goldhaber SZ, Yusen RD, Hernandez AF, Korjian S, Daaboul Y, Gold A, Harrington RA, Chi G. |date=2017 |title= The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification |url= https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0037-1603929#TB17006-7 |journal= TH Open |volume= 01 |issue=01 |pages= e56-e65 |doi= 10.1055/s-0037-1603929 |access-date= }}</ref><ref name="pmid21436241">{{cite journal| author=Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH et al.| title=Predictive and associative models to identify hospitalized medical patients at risk for VTE. | journal=Chest | year= 2011 | volume= 140 | issue= 3 | pages= 706-14 | pmid=21436241 | doi=10.1378/chest.10-1944 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21436241 }} </ref> | |||
=== | |||
=== | |||
==IMPROVEDD VTE Risk Score Calculator== | ==IMPROVEDD VTE Risk Score Calculator== | ||
Shown below is the calculator for IMPROVEDD Score for VTE (check all the boxes that apply): | Shown below is the calculator for IMPROVEDD Score for VTE (check all the boxes that apply): | ||
{{#widget: | {{#widget:IMPROVEDDScore2}} | ||
==Interpretation== | ==Interpretation== | ||
| Line 25: | Line 21: | ||
* Score = 4: Predicted Risk of Symptomatic VTE is 1.6% at 35-42 days and 1.9% at 77 days | * Score = 4: Predicted Risk of Symptomatic VTE is 1.6% at 35-42 days and 1.9% at 77 days | ||
* Score ≥ 5: Predicted Risk of Symptomatic VTE is 2.2% at 35-42 days and 2.7% at 77 days | * Score ≥ 5: Predicted Risk of Symptomatic VTE is 2.2% at 35-42 days and 2.7% at 77 days | ||
==See also== | ==See also== | ||
| Line 33: | Line 27: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Calculator]] | [[Category:Calculator]] | ||
Latest revision as of 17:42, 30 November 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2], Seyedmahdi Pahlavani, M.D. [3], Anmol Pitliya, M.B.B.S. M.D.[4]
Synonyms and keywords:
Overview
The IMPROVEDD VTE Risk Score, which incorporates D-dimer measurement into the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) score, refines the prediction of symptomatic venous thromboembolism (including symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, and death related to venous thromboembolism) events in acutely ill hospitalized patients up to 77 days of hospitalization.
IMPROVEDD VTE Risk Score
The IMPROVEDD VTE Risk Score, which incorporates D-dimer measurement into the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) score, refines the prediction of symptomatic venous thromboembolism (including symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, and death related to venous thromboembolism) events in acutely ill hospitalized patients up to 77 days of hospitalization.[1][2]
IMPROVEDD VTE Risk Score Calculator
Shown below is the calculator for IMPROVEDD Score for VTE (check all the boxes that apply):
Interpretation
- Score = 0: Predicted Risk of Symptomatic VTE is 0.4% at 35-42 days and 0.5% at 77 days
- Score = 1: Predicted Risk of Symptomatic VTE is 0.6% at 35-42 days and 0.7% at 77 days
- Score = 2: Predicted Risk of Symptomatic VTE is 0.8% at 35-42 days and 1.0% at 77 days
- Score = 3: Predicted Risk of Symptomatic VTE is 1.2% at 35-42 days and 1.4% at 77 days
- Score = 4: Predicted Risk of Symptomatic VTE is 1.6% at 35-42 days and 1.9% at 77 days
- Score ≥ 5: Predicted Risk of Symptomatic VTE is 2.2% at 35-42 days and 2.7% at 77 days
See also
References
- ↑ Gibson CM, Spyropoulos AC, Cohen AT, Hull RD, Goldhaber SZ, Yusen RD, Hernandez AF, Korjian S, Daaboul Y, Gold A, Harrington RA, Chi G. (2017). "The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification". TH Open. 01 (01): e56–e65. doi:10.1055/s-0037-1603929.
- ↑ Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH; et al. (2011). "Predictive and associative models to identify hospitalized medical patients at risk for VTE". Chest. 140 (3): 706–14. doi:10.1378/chest.10-1944. PMID 21436241.